基于分子分型指导的复发性子宫内膜癌的精准药物治疗及预后价值

徐蕊, 左丽, 杜琼, 程玺, 翟青

中国药学杂志 ›› 2023, Vol. 58 ›› Issue (12) : 1147-1154.

PDF(1279 KB)
PDF(1279 KB)
中国药学杂志 ›› 2023, Vol. 58 ›› Issue (12) : 1147-1154. DOI: 10.11669/cpj.2023.12.012
论著

基于分子分型指导的复发性子宫内膜癌的精准药物治疗及预后价值

  • 徐蕊1, 左丽2, 杜琼1,3,4, 程玺2,4,5*, 翟青1,3,4*
作者信息 +

Precise Drug Therapy of Recurrent Endometrial Cancer Based on Molecular Typing Guidance and Its Prognostic Value

  • XU Rui1, ZUO Li2, DU Qiong1,3,4, CHENG Xi2,4,5*, ZHAI Qing1,3,4*
Author information +
文章历史 +

摘要

目的 子宫内膜癌(endometrial carcinoma,EC)是女性三大常见的妇科恶性肿瘤之一。复发或转移及特殊病理类型的EC一直是临床诊治的难点,其治疗选择仍然有限,且缺乏显著的生存期改善。方法 近年来精准分型和个体化治疗开始主导抗肿瘤药物的治疗选择,国内外诊疗指南已将分子分型融入到预后风险分组中,对于改善高危复发性EC患者的治疗结局具有重要意义。结果和结论 本文旨在结合特定分子特征在复发性EC诊疗中的应用及风险分层指引,总结探讨复发性EC临床诊治实际中精准药物治疗依据及预后价值,具有临床指导意义。

Abstract

OBJECTIVE Endometrial carcinoma (EC) is one of the three most common gynecological malignancies in women. METHODS Recurrent or metastatic EC and special pathological types have always been difficult in clinical diagnosis and treatment, and their treatment options are still limited, and there is a lack of significant survival improvement. In recent years, accurate typing and individualized treatment have begun to dominate the treatment options of anti-tumor drugs. Domestic and foreign diagnosis and treatment guidelines have integrated molecular typing into the prognostic risk grouping, which is of great significance for improving the treatment outcomes of high-risk recurrent EC patients. RESULTS AND CONCLUSION The aim of this paper is to summarize and discuss the basis and prognostic value of precise drug therapy in the actual clinical diagnosis and treatment of recurrent EC in combination with the application of specific molecular characteristics and risk stratification guidelines, which has important clinical guiding significance.

关键词

复发性子宫内膜癌 / 分子分型 / 精准治疗 / 预后价值

Key words

recurrent endometrial carcinoma / molecular typing / precision therapy / prognostic value

引用本文

导出引用
徐蕊, 左丽, 杜琼, 程玺, 翟青. 基于分子分型指导的复发性子宫内膜癌的精准药物治疗及预后价值[J]. 中国药学杂志, 2023, 58(12): 1147-1154 https://doi.org/10.11669/cpj.2023.12.012
XU Rui, ZUO Li, DU Qiong, CHENG Xi, ZHAI Qing. Precise Drug Therapy of Recurrent Endometrial Cancer Based on Molecular Typing Guidance and Its Prognostic Value[J]. Chinese Pharmaceutical Journal, 2023, 58(12): 1147-1154 https://doi.org/10.11669/cpj.2023.12.012
中图分类号: R737.31   

参考文献

[1] SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics, 2020 [J]. CA Cancer J Clin, 2020, 70(1):7-30.
[2] XIE L L, LIN R C, LIN Z Q. Interpretation of 2022 NCCN clinical practice guidelines for uterine neoplasms (1st edition) [J]. Chin J Pract Gynecol Obstet(中国实用妇科与产科杂志) , 2021, 37(12):1227-1233.
[3] Professional Committee of Gynecologic Oncology, Chinese Anti-Cancer Association. Guidelines for the diagnosis and treatment of endometrial cancer (2021 edition) [J]. China Oncol(中国癌症杂志), 2021, 31 (6):501-512.
[4] XIE L L, LIN R C, LIN Z Q. Interpretation of international authoritative guidelines for diagnosis and treatment of endometrial cancer [J]. J Pract Obstet Gynecol(实用妇产科杂志), 2020, 36(6):428-432.
[5] TRAVAGLINO A, RAFFONE A, STRADELLA C, et al. Impact of endometrial carcinoma histotype on the prognostic value of the TCGA molecular subgroups [J]. Arch Gynecol Obstet, 2020, 301(6):1355-1363.
[6] CHENG A S, LI J, LIN Z Q. Interpretation of the 2020 ESGO-ESTRO-ESP guidelines for the management of patients with endometrial cancer [J]. Chin J Pract Gynecol Obstet(中国实用妇科与产科杂志), 2021, 37(3):336-341.
[7] The Society of Gynecoligical Cancer of China Anti-cancer Association, Chinese Society of Pathology of the Chinese Medical Association, National Pathology Quality Control Center. The Chinese expert consensus recommendations on molecular testing in endometrial cancer (2021 edition) [J]. China Oncol (中国癌症杂志), 2021, 31(11):1126-1144.
[8] KYO S, NAKAYAMA K. Endometrial cancer as a metabolic disease with dysregulated PI3K signaling:shedding light on novel therapeutic strategies [J]. Int J Mol Sci, 2020, 21(17):6073. Doi:10.3390/ijms21176073.
[9] URICK M E, BELL D W. Clinical actionability of molecular targets in endometrial cancer [J]. Nat Rev Cancer, 2019, 19(9):510-521.
[10] O'MALLEY D M, BARIANI G M, CASSIER P A, et al. Pembrolizumab in patients with microsatellite instability-high advanced endometrial cancer:Results from the KEYNOTE-158 study [J]. J Clin Oncol, 2022, 40(7):752-762.
[11] KASHERMAN L, AHRARI S, LHEUREUX S. Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer [J]. Future Oncol, 2021, 17(8):877-892.
[12] OAKNIN A, TINKER A V, GILBERT L, et al. Clinical activity and safety of the anti-programmed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair-deficient endometrial cancer:a nonrandomized phase 1 clinical trial [J]. JAMA Oncol, 2020, 6(11):1766-1772.
[13] BERGER A A, DAO F, LEVINE D A. Angiogenesis in endometrial carcinoma:therapies and biomarkers, current options, and future perspectives [J]. Gynecol Oncol, 2021, 160(3):844-850.
[14] GILLEN J, MILLS K A, DVORAK J, et al. Imaging biomarkers of adiposity and sarcopenia as potential predictors for overall survival among patients with endometrial cancer treated with bevacizumab [J]. Gynecol Oncol Rep, 2019, 30:100502. Doi:10.1016/j.gore.2019.100502.
[15] CHEN H, LIANG M, MIN J. Efficacy and safety of bevacizumab-combined chemotherapy for advanced and recurrent endometrial cancer:a systematic review and meta-analysis [J]. Balkan Med J, 2020, 38(1):7-12.
[16] LORUSSO D, FERRANDINA G, COLOMBO N, et al. Carboplatin-paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced or recurrent endometrial cancer:MITO END-2-A randomized phase II trial [J]. Gynecol Oncol, 2019, 155(3):406-412.
[17] MUSACCHIO L, CARUSO G, PISANO C, et al. PARP inhibitors in endometrial cancer:current status and perspectives [J]. Cancer Manag Res, 2020, 12:6123-6135. Doi:10.2147/CMAR.S221001.
[18] SHEN K, YANG L, LI FY, et al. Research progress of PARP inhibitor monotherapy and combination therapy for endometrial cancer [J]. Curr Drug Targets, 2022, 23(2):145-155.
[19] MAKKER V, TAYLOR M H, AGHAJANIAN C, et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer [J]. J Clin Oncol, 2020, 38(26):2981-2992.
[20] MAKKER V, COLOMBO N, CASADO HERRáEZ A, et al. Lenvatinib plus pembrolizumab for advanced endometrial cancer [J]. N Engl J Med, 2022, 386(5):437-448.
[21] MUSACCHIO L, BOCCIA S M, CARUSO G, et al. Immune checkpoint inhibitors:A promising choice for endometrial cancer patients? [J]. J Clin Med, 2020, 9(6):1721. Doi:10.3390/jcm9061721.
[22] POST C C B, WESTERMANN A M, BOSSE T, et al. PARP and PD-1/PD-L1 checkpoint inhibition in recurrent or metastatic endometrial cancer [J]. Crit Rev Oncol Hematol, 2020, 152:102973. Doi:10.1016/j.critrevonc.2020.102973.
[23] LOUKOVAARA M, PASANEN A, BüTZOW R. Molecular classification of endometrial carcinoma:a clinically oriented review [J]. J Clin Pathol, 2022. Doi:10.1136/jclinpath-2022-208345.
[24] COSGROVE C M, BARRINGTON D, BACKES F J. Impact of molecular classification on treatment paradigms in uterine cancers [J]. Curr Oncol Rep, 2021, 23(7):75. Doi:10.1007/s11912-021-01073-3.
[25] ZANNONI G F, SANTORO A, D'ALESSANDRIS N, et al. Biomarker characterization in endometrial cancer in Italy:first survey data analysis [J]. Pathologica, 2022, 114(3):189-198.
[26] LEóN-CASTILLO A, BRITTON H, MCCONECHY M K, et al. Interpretation of somatic POLE mutations in endometrial carcinoma [J]. J Pathol, 2020, 250(3):323-335.
[27] OAKNIN A, BOSSE T J, CREUTZBERG C L, et al. Endometrial cancer:ESMO clinical practice guideline for diagnosis, treatment and follow-up [J]. Ann Oncol, 2022, 33(9):860-877.
[28] JAMIESON A, THOMPSON E F, HUVILA J, et al. p53abn rndometrial cancer:understanding the most aggressive endometrial cancers in the era of molecular classification [J]. Int J Gynecol Cancer, 2021, 31(6):907-913.
[29] LESLIE K K, FILIACI V L, MALLEN A R, et al. Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer:An NRG Oncology study [J]. Gynecol Oncol, 2021, 161(1):113-121.
[30] THIEL K W, DEVOR E J, FILIACI V L, et al. TP53 sequencing and p53 immunohistochemistry predict outcomes when bevacizumab is added to frontline chemotherapy in endometrial cancer:an NRG oncology/gynecologic oncology group study [J]. J Clin Oncol, 2022, 40(28):3289-3300. Doi:10.1200/JCO.21.02506.
[31] JÖNSSON J M, BÅÅTH M, BJÖRNHEDEN I, et al. Homologous recombination repair mechanisms in serous endometrial cancer [J]. Cancers (Basel), 2021, 13(2):254. Doi:10.3390/cancers13020254.
[32] DE JONGE M M, AUGUSTE A, VAN WIJK L M, et al. Frequent homologous recombination deficiency in high-grade endometrial carcinomas [J]. Clin Cancer Res, 2019, 25(3):1087-1097.
[33] FAN H L. Progresson anticancer effects of PD-1/PD-L1 checkpoint inhibitions [J], Chin Pharm J(中国药学杂志), 2020, 55(16):1321-1324.
[34] LU L, LI Y, LUO R, et al. Prognostic and clinicopathological role of PD-L1 in endometrial cancer:a meta-analysis [J]. Front Oncol, 2020, 10:632. Doi:10.3389/fonc.2020.00632.
[35] BELLONE S, ROQUE D M, SIEGEL E R, et al. A phase 2 evaluation of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability [J]. Cancer, 2022, 128(6):1206-1218.
[36] MANNING-GEIST B L, LIU Y L, DEVEREAUX K A, et al. Microsatellite instability-high endometrial cancers with MLH1 promoter hypermethylation have distinct molecular and clinical profiles [J]. Clin Cancer Res, 2022, 28(19):4302-4311. Doi:10.1158/1078-0432.CCR-22-0713.
[37] COLL-DE L A, MARTINEZ-GARCIA E, DITTMAR G, et al. Prognostic biomarkers in endometrial cancer:A systematic review and meta-analysis [J]. J Clin Med, 2020, 9(6):1900. Doi:10.3390/jcm9061900.
[38] WORTMAN B G, NOUT R A, BOSSE T, et al. Selecting adjuvant treatment for endometrial carcinoma using molecular risk factors [J]. Curr Oncol Rep, 2019, 21(9):83. Doi:10.1007/s11912-019-0825-z.

基金

上海市闵行区自然科学研究课题资助(2022MHZ040);上海市闵行区卫生健康系统优秀青年药学人才计划项目资助(mwyjyx03);上海市闵行区卫生健康委员会科研课题资助(2020MW47)
PDF(1279 KB)

Accesses

Citation

Detail

段落导航
相关文章

/